|  |
| --- |
| **Supplementary Table 4. Characteristics of Gastric Cancers in Long-Term Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Users in Weighted Cohorts (cDDD ≥ 180 days) a** |
|  | PPI users(n=411) | H2RA users(n=397) | *P* |
| Sex |  |  |  |
| 　 | Male | 307 (74.8%) | 293 (73.8%) | 0.749 |
| 　 | Female | 104 (25.2%) | 104 (26.2%) |  |
| Age |  |  | 0.990 |
| 　 | 40-49 | 20 (5.0%) | 21 (5.3%) |  |
| 　 | 50-59 | 102 (24.8%) | 94 (23.6%) |  |
| 　 | 60-69 | 153 (37.3%) | 151 (38%) |  |
| 　 | 70-79 | 110 (26.6%) | 108 (27.3%) |  |
| 　 | ≥80 | 26 (6.2%) | 23 (5.8%) |  |
| Calendar period |  |  | 0.725 |
| 　 | 2004-2006 | 323 (78.6%) | 309 (77.8%) |  |
| 　 | 2007-2009 | 71 (17.2%) | 76 (19.2%) |  |
| 　 | 2010-2012 | 15 (3.7%) | 10 (2.5%) |  |
| 　 | 2013-2015 | 2 (0.5%) | 2 (0.5%) |  |
| Income |  |  | 0.842 |
| 　 | 1-3 (low) | 108 (26.3%) | 104 (26.3%) |  |
| 　 | 4-7 (mid) | 112 (27.2%) | 115 (28.9%) |  |
| 　 | 8-10 (high) | 191 (46.5%) | 178 (44.7%) |  |
| BMI (kg/m2) |  |  | 0.556 |
| 　 | Mean (SD) | 24.0 (2.25) | 23.8 (2.63) |  |
| Smoking |  |  | 0.556 |
| 　 | Never | 209 (50.9%) | 197 (49.7%) |  |
| 　 | Former | 88 (21.4%) | 97 (24.5%) |  |
| 　 | Current | 114 (27.7%) | 103 (25.8%) |  |
| Alcohol (times/week) |  |  | 0.743 |
| 　 | No  | 254 (61.9%) | 254 (64.0%) |  |
| 　 | 1-2 | 68 (16.6%) | 66 (16.4%) |  |
| 　 | ≥3  | 89 (21.6%) | 77 (19.4%) |  |
| GERD |  |  | 0.695 |
| 　 | Yes | 139 (33.9%) | 140 (50.1%) |  |
| 　 | No | 272 (66.1%) | 257 (64.8%) |  |
| Ulcer |  |  | 0.112 |
| 　 | Yes | 229 (55.8%) | 243 (61.3%) |  |
| 　 | No | 182 (44.2%) | 154 (38.7%) |  |
| Charlson Comorbidity Index |  |  |  |
| 　 | Mean (SD) | 2.7 (1.5) | 2.7 (1.5) |  |
| Use of Aspirin |  |  | 0.178 |
| 　 | Yes | 93 (22.7%) | 75 (18.9%) |  |
| 　 | No | 318 (77.3%) | 322 (81.1%) |  |
| Use of Metformin |  |  | 0.876 |
| 　 | Yes | 60 (14.6%) | 59 (15.0%) |  |
| 　 | No | 351 (85.4%) | 338 (85.1%) |  |
| Use of Statin |  |  | 0.992 |
| 　 | Yes | 90 (22.0%) | 87 (22.0%) |  |
| 　 | No | 321 (78.0%) | 310 (78%) |  |
| cDDD, cumulative defined daily dose; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor; CI, confidence interval; BMI, body mass index; GERD, gastroesophageal reflux disease; a PPI long-term use was defined as only PPI use, PPI ≥ 180 cDDD-days, and combined use, PPI ≥ 180 cDDD-days and H2RA < 180 cDDD-days or PPI ≥ 180 cDDD-days and H2RA ≥ 180 cDDD-days. H2RA long-term use was defined as only H2RA use, H2RA ≥ 180 cDDD-days, and combined use of H2RA ≥ 180 cDDD-days and PPI < 180 cDDD-days. |